

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

PANGENOMIC HEALTH INC. (the "Company")
102 – 3800 Wesbrook Mall
Vancouver, BC V6S 2L9

Item 2. Date of Material Change

July 12, 2023

Item 3. News Release

The news release was issued on July 13, 2023 and disseminated by Cision.

Item 4. Summary of Material Change

On July 13, 2023, the Company announced the resignation of two directors of the Company.

Item 5. Full Description of Material Change

The Company announced that independent directors of the Company, Peter Green and Jonathan Lutz, tendered their resignations effective as of July 12, 2023.

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Tammy Gillis
Chief Financial Officer, Treasurer and Secretary
(778) 743-4642

Item 9. Date of Report

July 13, 2023

SCHEDULE "A"

NEWS RELEASE

(See attached)



PanGenomic Health Announces Director Resignations

VANCOUVER, BC, July 13, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), announced today that independent directors, Peter Green and Jonathan Lutz, tendered their resignations effective as of July 12, 2023.

"We wish to thank Peter and Jonathan for all of their valuable guidance as PanGenomic matured from a private health tech startup to one of the first publicly-listed benefit companies in both Canada and the UK last year", said Robert Nygren, Executive Chair and Co-Founder of PanGenomic Health.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedar.com.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE PanGenomic Health Inc.

View original content to download multimedia:
<http://www.newswire.ca/en/releases/archive/July2023/13/c1087.html>

%SEDAR: 00039388E

For further information: Jerry Lai, Investor Relations, PanGenomic Health Inc., 778 743 4642,

ir@pangenomic.com; Maryam Marissen, President & CEO, PanGenomic Health Inc., 778 743 4642,
info@pangenomic.com

CO: PanGenomic Health Inc.

CNW 17:30e 13-JUL-23